+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining a PD-1 inhibitor called sintilimab with radiotherapy and immunonutrition support in patients with locally advanced or early stage esophageal squamous cell carcinoma who cannot tolerate standard chemoradiotherapy. This phase II, single-arm multicenter trial focuses on patients who have positive PD-L1 expression and are unsuitable for platin-based chemoradiotherapy due to factors like older age or other health issues. Previous studies have shown promising results using immunotherapy with chemoradiotherapy, motivating this investigation. Participants will receive concurrent treatment with radiotherapy doses of 50-60 Gy delivered in 25-30 sessions along with 200 mg of sintilimab every three weeks. Alongside these treatments, they will take an enteral nutritional emulsion TPF-T daily, adjusted between 600 and 1600 ml based on their nutritional status. After radiotherapy, consolidation immunotherapy with sintilimab continues for up to one year. This combined approach aims to improve progression-free survival while monitoring safety. Throughout the study, participants will undergo evaluations including imaging to assess tumor response, laboratory tests to monitor organ function, and tracking of adverse events. The primary outcome is the progression-free survival rate at one year, with secondary outcomes including response rates, overall survival, and safety measures at multiple time points up to three years. Participants will be closely monitored for treatment tolerance and disease progression during and after therapy, with the total study duration extending through the follow-up period.

Age: 18Years - 80YearsAll GendersPhase 2
10 locations